[go: up one dir, main page]

TNSN95081A1 - Procede pour la synthese de sulfoxydes substitues - Google Patents

Procede pour la synthese de sulfoxydes substitues

Info

Publication number
TNSN95081A1
TNSN95081A1 TNTNSN95081A TNSN95081A TNSN95081A1 TN SN95081 A1 TNSN95081 A1 TN SN95081A1 TN TNSN95081 A TNTNSN95081 A TN TNSN95081A TN SN95081 A TNSN95081 A TN SN95081A TN SN95081 A1 TNSN95081 A1 TN SN95081A1
Authority
TN
Tunisia
Prior art keywords
purposes
synthesis
sulfoxide
alkaline salts
substituted
Prior art date
Application number
TNTNSN95081A
Other languages
English (en)
Inventor
Erik Magnus Larsson
Urban Jan Stenhede
Henrik Sorensen
Unge Per Oskar Sverker Von
Hanna Kristina Cotton
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN95081(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN95081A1 publication Critical patent/TNSN95081A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN NOUVEAU PROCEDE POUR LA SYNTHESE ENANTIOSELECTIVE DES ENANTIOMERES SIMPLE D'OMEPRAZOLE OU DE SES SELS ALCALINS, D'AUTRES 2-(2- PYRIDINYLMETHYLE-SULFINYLE)-1H-BENZIMIDAZOLES SUBSTITUES OPTIQUEMENT PURS AINSI QUE D'AUTRES SULFOXYDES APPARENTES PAR LEUR CONSTITUTION OU LEURS SELS ALCALINS. LE PROCEDE REVENDIQUE EST UNE OXYDATION ASYMETRIQUE D'UN SULFURE PROCHIRAL DES ENANTIOMERE SIMPLES OU D'UNE FORME ENRICHIE DE MANIERE ENANTIOMERE DU SULFOXYDE APPARENTE. L'APPLICATION REVENDIQUE EGALEMENT LES PRODUITS SULFOXYDES ENANTIOMERES PREPARES PAR LE PROCEDE ET LEUR UTILISATIONS EN MEDECINE
TNTNSN95081A 1994-07-15 1995-07-13 Procede pour la synthese de sulfoxydes substitues TNSN95081A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider

Publications (1)

Publication Number Publication Date
TNSN95081A1 true TNSN95081A1 (fr) 1996-02-06

Family

ID=20394753

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN95081A TNSN95081A1 (fr) 1994-07-15 1995-07-13 Procede pour la synthese de sulfoxydes substitues

Country Status (41)

Country Link
US (1) US5948789A (fr)
EP (1) EP0773940B2 (fr)
JP (1) JP3795917B2 (fr)
KR (1) KR100356252B1 (fr)
CN (1) CN1070489C (fr)
AR (1) AR003443A1 (fr)
AT (1) ATE242233T1 (fr)
AU (1) AU688074B2 (fr)
BR (1) BR9508292A (fr)
CA (1) CA2193994C (fr)
CZ (1) CZ297987B6 (fr)
DE (1) DE69530987T3 (fr)
DK (1) DK0773940T4 (fr)
DZ (1) DZ1911A1 (fr)
EE (1) EE03354B1 (fr)
EG (1) EG24534A (fr)
ES (1) ES2199998T5 (fr)
FI (2) FI117830B (fr)
HR (1) HRP950401B1 (fr)
HU (1) HU226361B1 (fr)
IL (1) IL114477A (fr)
IS (1) IS1772B (fr)
MA (1) MA23611A1 (fr)
MX (1) MX9700358A (fr)
MY (1) MY113180A (fr)
NO (1) NO312101B1 (fr)
NZ (1) NZ289959A (fr)
PL (1) PL186342B1 (fr)
PT (1) PT773940E (fr)
RU (1) RU2157806C2 (fr)
SA (1) SA95160294B1 (fr)
SE (1) SE504459C2 (fr)
SI (1) SI0773940T2 (fr)
SK (1) SK284059B6 (fr)
TN (1) TNSN95081A1 (fr)
TR (1) TR199500861A2 (fr)
TW (1) TW372971B (fr)
UA (1) UA47409C2 (fr)
WO (1) WO1996002535A1 (fr)
YU (1) YU49475B (fr)
ZA (1) ZA955724B (fr)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SK179899A3 (en) 1997-07-03 2001-12-03 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2320963A1 (fr) * 1998-01-30 1999-08-05 Sepracor, Inc. Compositions et procedes d'utilisation du r-lansoprazole
AU3870599A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. R-rabeprazole compositions and methods
AU3967399A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. S-rabeprazole compositions and methods
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1191025B1 (fr) 1999-06-30 2005-06-22 Takeda Pharmaceutical Company Limited Cristaux de lansoprazole
AU6727700A (en) * 1999-08-25 2001-03-19 Takeda Chemical Industries Ltd. Process for the preparation of optically active sulfoxide derivatives
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
ES2273829T3 (es) * 2000-04-28 2007-05-16 Takeda Pharmaceutical Company Limited Procedimiento para producir derivado de sulfoxido opticamente activo.
KR100869677B1 (ko) 2000-05-15 2008-11-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
DE60131649T2 (de) 2000-05-15 2008-10-30 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung eines kristalls
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
TWI290922B (en) 2000-12-01 2007-12-11 Takeda Chemical Industries Ltd Production method of crystals
US7064214B2 (en) * 2001-04-13 2006-06-20 Apsinterm Llc Methods of preparing sulfinamides and sulfoxides
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
WO2003063840A2 (fr) * 2002-01-25 2003-08-07 Santarus, Inc. Administration par voie muqueuse d'inhibiteurs de la pompe a protons
WO2003074514A1 (fr) * 2002-03-05 2003-09-12 Astrazeneca Ab Sels d'alkylammonium d'omeprazole et d'esomeprazole
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2004002982A2 (fr) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1552833B1 (fr) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Procédé de préparation d'un iosmère optiquement actif du lansoprazole
AU2003278406A1 (en) 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
ATE553103T1 (de) 2002-12-06 2012-04-15 Nycomed Gmbh Verfahren zur herstellung von (s)-pantoprazol
US7452998B2 (en) 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
CN100500660C (zh) * 2002-12-06 2009-06-17 尼可姆公司 用于制备泮托拉唑(pantoprazole)的方法
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
AR046245A1 (es) * 2002-12-16 2005-11-30 Ranbaxy Lab Ltd Sales de calcio de rabeprazol
US7507829B2 (en) 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
CN1723208A (zh) * 2003-01-07 2006-01-18 兰贝克赛实验室有限公司 咪唑衍生物的镁盐
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
MXPA05009183A (es) * 2003-02-28 2005-10-20 Ranbaxy Lab Ltd Polimorfos de s-omeprazol.
EP1601667A2 (fr) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Formes solides cristallines et amorphes de pantoprazole et procedes de preparation de ces formes
JP4355703B2 (ja) * 2003-03-13 2009-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 歯ぎしりの予防剤または治療剤
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
US20060281782A1 (en) * 2003-03-28 2006-12-14 Avraham Cohen Method for the enantioselective preparation of sulphoxide derivatives
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
EP1615913A2 (fr) 2003-06-10 2006-01-18 Teva Pharmaceutical Industries Limited Procede de preparation de benzimidazoles 2- (pyridinyl)methyl]sulfinyle substitues et nouveau derives chlorures de pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
WO2005054228A1 (fr) * 2003-12-05 2005-06-16 Hetero Drugs Limited Procede de preparation d'enantiomeres de pyridinylmethylsulfinyl- benzamide substitues
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
DE602004022337D1 (de) * 2004-04-28 2009-09-10 Hetero Drugs Ltd Verfahren zur herstellung von pyridinylmethyl-1h-benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1748998B1 (fr) * 2004-05-28 2010-01-27 Hetero Drugs Limited Nouveau procede de synthese stereoselective de sulfoxydes de benzimidazole
CA2568652A1 (fr) * 2004-06-02 2005-12-15 Altana Pharma Ag Procede permettant la preparation de composes pyridin-2-yl-methyl-sulfinyl-1h-benzimidazol
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
NZ551970A (en) 2004-06-24 2010-01-29 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
FR2876101B1 (fr) * 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
SI1802584T1 (sl) * 2004-10-11 2010-01-29 Ranbaxy Lab Ltd Postopki za pripravo substituiranih sulfoksidov
US7592111B2 (en) * 2004-11-05 2009-09-22 Xerox Corporation Imaging member
CA2597632C (fr) * 2005-03-25 2012-05-15 Livzon Pharmaceutical Group Inc. Derives de sulfoxyde substitues, methodes de synthese desdits derives et applications desdits derives
CN101098867B (zh) * 2005-03-25 2010-08-11 丽珠医药集团股份有限公司 取代的亚砜类化合物和其制备方法及用途
RU2007145207A (ru) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции
US8247566B2 (en) * 2005-06-08 2012-08-21 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
KR20080076924A (ko) * 2005-12-05 2008-08-20 아스트라제네카 아베 에소메프라졸 비-염 형태의 제조를 위한 신규 방법
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CA2631459A1 (fr) 2005-12-28 2007-07-05 Union Quimico Farmaceutica, S.A. Procede pour la preparation de l'enantiomere (s) d'omeprazole
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US7786309B2 (en) * 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
MX2008016196A (es) 2006-07-05 2009-01-20 Lupin Ltd Proceso para la preparacion de enantiomeros opticamente puros u opticamente enriquecidos de compuestos de sulfoxido.
EP2054403A1 (fr) * 2006-08-08 2009-05-06 Jubilant Organosys Limited Procédé de production de composés de sulfoxyde
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
US20110009624A9 (en) 2006-10-13 2011-01-13 Masato Ueda Benzimidazole compounds having gastric acid secretion inhibitory action
EP1947099A1 (fr) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
EP2842953A1 (fr) 2007-02-21 2015-03-04 Cipla Limited Procédé pour la Préparation de Ésoméprazole Magnésium Dihydraté
RU2341524C1 (ru) * 2007-05-02 2008-12-20 Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) СПОСОБ ПОЛУЧЕНИЯ ОПТИЧЕСКИ АКТИВНОГО 5-МЕТОКСИ-2-((4-МЕТОКСИ-3,5-ДИМЕТИЛПИРИДИН-2-ИЛ)МЕТИЛСУЛЬФИНИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛА
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
US20100210848A1 (en) * 2007-10-03 2010-08-19 Ipca Laboratories Ltd. Process for optically active sulfoxide compounds
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CA2702356C (fr) 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Formulation pharmaceutique independante de la prise alimentaire comprenant un inhibiteur de la pompe a protons pour le traitement des troubles gastro-intestinaux
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
BRPI0909651A2 (pt) 2008-03-10 2015-09-22 Takeda Pharmaceutical cristal, agente farmacêutico, método para tratar ou evitar doença, uso do cristal, e, método para a produção de um cristal
WO2009117489A1 (fr) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Procédé de préparation du dexlansoprazole et autres formes polymorphes
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
WO2009145368A1 (fr) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Procédé amélioré de préparation de (s)-oméprazole à partir d'un racémate d'oméprazole à l’aide d'un agent de résolution optique
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2264024A1 (fr) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Procédé de préparation d'inhibiteurs de la pompe à protons énantiomériquement enrichis
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) * 2009-02-16 2010-08-25 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (fr) 2009-02-24 2010-09-02 Cipla Limited Polymorphe de l'ésoméprazole de potassium et sa préparation
CZ2009172A3 (cs) * 2009-03-17 2010-09-29 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
EP2438057A4 (fr) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd Procédé d'élaboration de composés sulfoxyde
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
EP2499125B1 (fr) 2009-11-12 2016-01-27 Hetero Research Foundation Procédé de dédoublement de l'oméprazole
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CA2803673A1 (fr) 2010-06-24 2011-12-29 Cipla Limited Sels et polymorphes de la dexrabeprazole
CN101914090B (zh) * 2010-08-13 2013-03-20 埃斯特维华义制药有限公司 左旋奥美拉唑的制备方法
CN102558150B (zh) * 2010-12-31 2014-03-12 正大天晴药业集团股份有限公司 取代亚砜化合物的合成方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) * 2011-09-02 2013-03-20 扬子江药业集团上海海尼药业有限公司 一种右兰索拉唑的制备方法
CN102329302A (zh) * 2011-10-22 2012-01-25 刘强 一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) * 2011-10-25 2012-04-11 广东华南药业集团有限公司 高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) * 2011-10-28 2012-05-02 成都欣捷高新技术开发有限公司 一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) * 2011-10-31 2013-08-27 르노삼성자동차 주식회사 전기자동차의 공기 흡입 장치
WO2013140120A1 (fr) 2012-03-22 2013-09-26 Cipla Limited Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) * 2012-04-27 2014-01-22 南京优科生物医药研究有限公司 一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) * 2012-12-31 2015-01-14 康普药业股份有限公司 埃索美拉唑钠合成生产方法
CN103113351B (zh) * 2013-03-08 2015-01-21 苏州特瑞药业有限公司 一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
WO2015155281A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et d'inhibiteurs de la pompe à protons
WO2015155307A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de pompe à protons
EP2980086B1 (fr) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé efficace pour la préparation d'ésoméprazole (S)-binol complexe
KR20170098843A (ko) 2014-12-26 2017-08-30 고쿠리츠다이가쿠호우진 도쿄다이가쿠 광학 활성의 프로톤 펌프 저해 화합물의 제조 방법
CN104610226A (zh) * 2014-12-31 2015-05-13 广东东阳光药业有限公司 一种右兰索拉唑的不对称氧化方法
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
CN105218391B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 L‑酒石酸单酯单酰胺类化合物
CN105218392B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 D‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) * 2016-05-17 2019-05-03 杭州华东医药集团新药研究院有限公司 左旋泮托拉唑的工业化生产方法
CN106083818A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) * 2016-08-10 2019-06-11 上海万巷制药有限公司 一种高纯度埃索美拉唑钠的制备方法
KR102409502B1 (ko) * 2016-09-14 2022-06-16 위펑 제인 쳉 D-아미노산 옥시다제 (daao) 저해제로서 신규한 치환된 벤즈이미다졸 유도체
CN106632248A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种左旋泮托拉唑钠的制备工艺
CN106632249A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种制备(s)‑泮托拉唑钠的方法
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN113845510B (zh) * 2020-06-27 2025-02-18 鲁南制药集团股份有限公司 一种埃索美拉唑的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
WO1993006037A1 (fr) * 1991-09-16 1993-04-01 Catalytica, Inc. Procede et catalyseur de production de brome
WO1993024480A1 (fr) * 1992-06-01 1993-12-09 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridine et son utilisation medicinale
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution

Also Published As

Publication number Publication date
CA2193994C (fr) 2005-05-03
YU47695A (sh) 1998-07-10
SE504459C2 (sv) 1997-02-17
PL318165A1 (en) 1997-05-26
SI0773940T2 (sl) 2011-02-28
RU2157806C2 (ru) 2000-10-20
DE69530987D1 (de) 2003-07-10
DZ1911A1 (fr) 2002-02-17
MY113180A (en) 2001-12-31
ATE242233T1 (de) 2003-06-15
ZA955724B (en) 1996-01-15
SK4897A3 (en) 1997-08-06
HRP950401A2 (en) 1997-10-31
SE9402510D0 (sv) 1994-07-15
CN1157614A (zh) 1997-08-20
FI970102A0 (fi) 1997-01-10
SI0773940T1 (en) 2004-02-29
AU2994895A (en) 1996-02-16
DE69530987T3 (de) 2011-07-07
PL186342B1 (pl) 2003-12-31
IS1772B (is) 2001-06-01
HRP950401B1 (en) 2004-04-30
CZ6497A3 (en) 1997-06-11
SK284059B6 (sk) 2004-09-08
JP3795917B2 (ja) 2006-07-12
MX9700358A (es) 1997-04-30
US5948789A (en) 1999-09-07
AU688074B2 (en) 1998-03-05
IL114477A (en) 2001-07-24
YU49475B (sh) 2006-05-25
EG24534A (en) 2009-08-30
EP0773940B1 (fr) 2003-06-04
NZ289959A (en) 1998-01-26
NO312101B1 (no) 2002-03-18
AR003443A1 (es) 1998-08-05
HU226361B1 (en) 2008-09-29
CZ297987B6 (cs) 2007-05-16
DK0773940T3 (da) 2003-09-15
EE03354B1 (et) 2001-02-15
HUT76642A (en) 1997-10-28
DK0773940T4 (da) 2011-02-07
EP0773940B2 (fr) 2010-11-17
FI117672B (fi) 2007-01-15
ES2199998T3 (es) 2004-03-01
WO1996002535A1 (fr) 1996-02-01
DE69530987T2 (de) 2004-05-19
NO970153L (no) 1997-01-14
SA95160294B1 (ar) 2006-07-31
NO970153D0 (no) 1997-01-14
EP0773940A1 (fr) 1997-05-21
HK1008331A1 (en) 1999-05-07
TR199500861A2 (tr) 1996-06-21
FI970102L (fi) 1997-01-10
ES2199998T5 (es) 2011-03-16
CA2193994A1 (fr) 1996-02-01
CN1070489C (zh) 2001-09-05
PT773940E (pt) 2003-10-31
IL114477A0 (en) 1995-11-27
MA23611A1 (fr) 1996-04-01
TW372971B (en) 1999-11-01
KR970704731A (ko) 1997-09-06
BR9508292A (pt) 1997-12-23
UA47409C2 (uk) 2002-07-15
SE9402510L (sv) 1996-01-16
WO1996002535A8 (fr) 1999-12-23
JPH10504290A (ja) 1998-04-28
KR100356252B1 (ko) 2002-11-18
FI117830B (fi) 2007-03-15
IS4406A (is) 1996-12-27

Similar Documents

Publication Publication Date Title
TNSN95081A1 (fr) Procede pour la synthese de sulfoxydes substitues
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
FR2656874B1 (fr) Procede de production et d'extraction d'anti-oxydants a partir d'une culture de micro-organismes et photobioreacteur pour la mise en óoeuvre de ce procede.
FR2556349B1 (fr) Procede perfectionne pour inhiber la croissance de micro-organismes dans un latex aqueux et produit obtenu
HUT68357A (en) Heterocyclic-cyclic-amine derivatives, pharmaceutical compositions containing them and process for their production
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
BE798195A (fr) Procede d'application de microcapsules sur des tissus et produits ainsi obtenus
TNSN87015A1 (fr) Nouvelles n-heterocyclyl-4-piperidinamines, compositions contenant des n-heterocyclyl-4-piperidinamines, procede de traitement les utilisant et procede pour preparer des n-heterocyclyl-4- piperidinamines
BE781802A (fr) Procede pour extraire un medicament vasoactif a partir des feuille de ginkgo biloba ainsi que preparations pharmaceutiques
BE876408A (fr) Procede enzymatique microbiologique pour la production d'aminoacides optiquement actifs en partant d'hydanthoines et/ou de derives carbamoyle racemiques
PT96198A (pt) Processo para a prparacao de derivados de benzil-rodanina substituidos uteis no tratamento de doencas inflamatorias do intestino
MA21529A1 (fr) Procede stereospecifiques pour la preparation des enantiomeres de la furo (3,4,c) pyridine et composes ainsi obtenus.
FR2621587B1 (fr) Derives du dimethyl-2,2 chromene, procede pour leur preparation et composition pharmaceutiques les contenant
FR2668148B1 (fr) Nouveau derive de 5h-benzodiazepine, compositions pharmaceutiques le contenant et procede pour les preparer.
OA07839A (fr) Procédé de traitement de l'huile de café et produit obtenu.
FR2687154B1 (fr) Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
HUT40116A (en) Process for production of new cristallic form of benzotiozin-dioxid
ATE223395T1 (de) Synthese von optisch reiner 4-aryl-2- hydroxytetronic
DE3872570D1 (de) Verfahren zur herstellung von 4,4'-bisphenol, dessen vorlaeufer und die herstellung des vorlaeufers.
AU4788696A (en) New derivatives of pyridine or pyridazine, process for production thereof and medicaments containing these compounds
FR2381760A1 (fr) Nouveau derive pyridyl-piperazine et procede pour sa preparation
DE59605316D1 (de) Verfahren zur herstellung von beta-amino-alpha-hydroxycarbonsäuren und deren derivaten
FR2673105B1 (fr) Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.